Difficulty: Medium
Average Score: 83%
Practice
Which of the following is the primary treatment for patent ductus arteriosus (PDA) in a preterm infant?
Correct answer
B
Rationale
In the case of a preterm infant with a patent ductus arteriosus (PDA), the primary treatment is typically indomethacin (Option B). Indomethacin is a nonsteroidal anti-inflammatory drug that helps to close the PDA by inhibiting prostaglandin synthesis. This medication is effective in promoting ductal closure in many preterm infants with PDA.
Antibiotics (Option A) are not the primary treatment for PDA. PDA is a cardiac condition related to the persistence of a fetal connection between the aorta and pulmonary artery. Antibiotics do not address the underlying issue of the open ductus arteriosus.
Corticosteroids (Option C) are not the primary treatment for PDA either. While corticosteroids have anti-inflammatory properties, they are not typically used as a first-line treatment for closing a PDA in preterm infants.
Surgery (Option D) is considered when medical management such as indomethacin fails to close the PDA or if the infant's condition deteriorates. However, surgery is usually reserved for cases where pharmacological interventions have been ineffective.
Educationally, understanding the appropriate treatment for PDA in preterm infants is crucial for pediatric clinical nurse specialists. It is essential to be knowledgeable about the pharmacological options available, their mechanisms of action, and the criteria for selecting the most appropriate treatment based on the infant's condition. This knowledge helps ensure optimal care and outcomes for these vulnerable patients.
Antibiotics (Option A) are not the primary treatment for PDA. PDA is a cardiac condition related to the persistence of a fetal connection between the aorta and pulmonary artery. Antibiotics do not address the underlying issue of the open ductus arteriosus.
Corticosteroids (Option C) are not the primary treatment for PDA either. While corticosteroids have anti-inflammatory properties, they are not typically used as a first-line treatment for closing a PDA in preterm infants.
Surgery (Option D) is considered when medical management such as indomethacin fails to close the PDA or if the infant's condition deteriorates. However, surgery is usually reserved for cases where pharmacological interventions have been ineffective.
Educationally, understanding the appropriate treatment for PDA in preterm infants is crucial for pediatric clinical nurse specialists. It is essential to be knowledgeable about the pharmacological options available, their mechanisms of action, and the criteria for selecting the most appropriate treatment based on the infant's condition. This knowledge helps ensure optimal care and outcomes for these vulnerable patients.